Auditive and Renal Long Term Outcomes - Risk After Aminoglycoside Therapy in Neonates (AURORA)

CompletedOBSERVATIONAL

Enrollment

226

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

September 15, 2018

Study Completion Date

September 15, 2018

Conditions

Hearing LossGentamicin Adverse ReactionRenal Tubular Disorder

Interventions

DIAGNOSTIC_TEST

Audiometry

Extended high-frequency (EHF; 9-16 kHz) audiometry

DIAGNOSTIC_TEST

Urine biomarkers for renal tubular function

Kidney Injury Molecule-1

DIAGNOSTIC_TEST

Blood pressure

Blood pressure right arm, measured With standard Methods 3 times

Trial Locations (1)

University Hospital of North Norway, Tromsø

All Listed Sponsors

lead

University Hospital of North Norway

OTHER

NCT03253614 - Auditive and Renal Long Term Outcomes - Risk After Aminoglycoside Therapy in Neonates (AURORA) | Biotech Hunter | Biotech Hunter